Laigo Bio BV, a Dutch biotech with a platform designed to promote the degradation of disease-causing proteins, has received €11.5 million in seed financing to advance early-stage programmes in oncology and autoimmunity. The financing was co-led by Kurma Partners of France and Curie Capital of the Netherlands. Other investors included France-based Argobio Studio, an incubator which participated in Laigo’s launch in 2022.
The European Commission launched a comprehensive package of measures in early December designed to realise the full potential of the single market for financial services. The package is a key component of the EU Savings and Investments Union (SIU) strategy, which aims to create a more integrated, efficient and competitive financial system and to support businesses across Europe in accessing funding.
The US Food and Drug Administration has approved a new gene therapy for spinal muscular atrophy (SMA), a neurological disorder that can lead to progressive muscle weakness and in the most severe cases, death. The therapy, Itvisma (onasemnogene abeparvovec), has the same active ingredient as the gene therapy Zolgensma, but formulated at a different concentration. Zolgensma was approved by the FDA in 2019 to treat paediatric patients with SMA. The newest therapy extends the treatment group to older individuals with a confirmed mutation in the survival motor neuron 1 (SMN1) gene.
Case Study
How argenx reached
Nasdaq as a small European biotech
Research Strategy
Epigenetic modulation in
pulmonary disease
By Björn Dahlöf
Interview
Exploring novel payloads
for antibody-drug conjugates
Interview with Adcytherix
Cell and Gene Therapy
Why synthetic gene
promoters matter
By Thilo Pohle
